SCHEMBL4716796

SCHEMBL4716796

CNC(CO)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3444514 1.00
SCHEMBL12133544 1.00
SCHEMBL21415834 0.83 TSHR (0.38)
SCHEMBL11569001 0.79
SCHEMBL16471118 0.79
SCHEMBL11569003 0.79
SCHEMBL13502646 0.79
SCHEMBL13108076 0.77
SCHEMBL17483144 0.77
SCHEMBL18218224 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887007-A2 Novel compounds AstraZeneca AB (SE) 2008-02-13 EP claimed
EP-1625126-B1 IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS ASTRAZENECA AB (SE) 2008-01-16 EP claimed
US-20060287355-A1 Imidazo and thiazolopyridines as jak3 kinase inhibitors ASTRAZENECA AB (SE) 2006-12-21 US claimed
US-7122570-B2 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2006-10-17 US claimed
US-20030232873-A1 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2003-12-18 US claimed
US-20260008787-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS INC (US) 2026-01-08 US disclosed
EP-4551577-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE Blossomhill Therapeutics, Inc. (US) 2025-05-14 EP disclosed
WO-2024015262-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2024-01-18 WO disclosed
WO-2022129890-A1 H4 ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2022-06-23 WO disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 US disclosed
US-10329263-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-25 US disclosed
US-10029993-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-07-24 US disclosed
EP-1625126-B1 IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS ASTRAZENECA AB (SE) 2008-01-16 EP disclosed
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2007-08-16 US disclosed
EP-1818325-A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION (US) 2007-08-15 EP disclosed
EP-1567464-B1 CATALYTIC HYDROGENERATION OF CARBON-HETEROATOM DOUBLE BONDS SOLVIAS AG (CH) 2007-04-18 EP disclosed
WO-2007014409-A1 PLEUROMUTILIN DERIVATIVES USEFUL AS ANTIBACTERIALS NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) 2007-02-08 WO disclosed
US-20060287355-A1 Imidazo and thiazolopyridines as jak3 kinase inhibitors ASTRAZENECA AB (SE) 2006-12-21 US disclosed
US-7122570-B2 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2006-10-17 US disclosed
US-20030232873-A1 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2003-12-18 US disclosed